Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
JOURNAL ARTICLE
Hafizah Sururul Nur Rakhmawati, Citrawati Dyah Kencono Wungu, Bambang Purwanto, Andre Andarianto
OBJECTIVES: To analyze the impact of exercise under hypoxic exposure versus normoxic exposure on blood glucose level, insulin level, and insulin sensitivity in people at risk of Type 2 diabetes mellitus (T2DM). MATERIALS AND METHODS: We systematically performed electronic searching on PubMed, Web of Science, ProQuest, and Scopus. Primary studies that met the inclusion criteria were analyzed using Revman 5.4.1. RESULTS: Nine randomized controlled trials were included in this meta-analysis...
2024: Tzu chi medical journal
#2
Yating Gao, Zhenghong Li, Yiming Wang, Haoling Zhang, Ke Huang, Yujie Fu, Shanqiong Xu, Qingna Li, Xingfang Liu, Guangde Zhang
OBJECTIVE: This study aims to map evidence from Randomized Controlled Trials (RCTs) and systematic reviews/Meta-analyses concerning the treatment of Diabetic Nephropathy (DN) with Traditional Chinese Medicine (TCM), understand the distribution of evidence in this field, and summarize the efficacy and existing problems of TCM in treating DN. The intention is to provide evidence-based data for TCM in preventing and treating DN and to offer a reference for defining future research directions...
2024: Frontiers in Endocrinology
#3
JOURNAL ARTICLE
Yitan Hou, Ze Hu, Feng Jiang, Qiuling Zhao, Chongjian Wang, Yuxiao Zhang
Objectives: This study aimed to estimate the life expectancy (LE) and health-adjusted life expectancy (HALE) of type 2 diabetes mellitus (T2DM) among the rural elderly population. Methods: A total of 10,318 participants aged 65 to 79 were derived from the Henan Rural Cohort. The LE and HALE were calculated via the Sullivan method and multistate life table. Results: Among 10,318 subjects, 1,325 suffered from T2DM at the baseline, and 394 participants had newly-developed T2DM. The results from the Sullivan method showed that the LE, HALE, and HALE/LE were 17...
2024: International Journal of Public Health
#4
JOURNAL ARTICLE
Frederico Ludwig da Costa, Lucas Strassburger Matzenbacher, Vicenzo Gheno, Maria Antônia Bertuzzo Brum, Laura Gomes Boabaid de Barros, Isabela Semmelmann Maia, Luiza Machado Blank, Lucas Friedrich Fontoura, Janine Alessi, Gabriela Heiden Telo
BACKGROUND: With one in five individuals aged 65 or older living with type 2 diabetes worldwide, it is crucial to acknowledge and address the challenges faced by this population. In this context, our study aims to evaluate the efficacy of a behavioral intervention model delivered through a smart speaker on mental health and diabetes self-care in the elderly with diabetes. METHODS: This is a single-center, pragmatic, parallel two-arm open randomized clinical trial involving elderly patients with type 2 diabetes...
March 21, 2024: Trials
#5
REVIEW
Qiqi Zhang, Shiwan Hu, Zishan Jin, Sicheng Wang, Boxun Zhang, Linhua Zhao
Objective: Affected by aging, the elderly diabetes patients have many pathological characteristics different from the young people, including more complications, vascular aging, cognitive impairment, osteoporosis, and sarcopenia. This article will explore their pathogenesis and the mechanism of Traditional Chinese medicine (TCM) intervention, and use the method of systematic review to evaluate the clinical application of TCM in elderly diabetes. Method: Searching for randomized controlled trials (RCTs) published from January 2000 to November 2023 in the following databases: Web of Science, Pubmed, Embase, Cochrane Library, Sinomed, China National Knowledge Internet, Wanfang and VIP...
2024: Frontiers in Pharmacology
#6
REVIEW
Tu N Nguyen, Fahed Ahmad, Richard I Lindley
With population ageing, drug trials are increasingly turning their attention to including older, frailer people. This review aimed to provide an overview of how frailty was assessed in published studies related to clinical pharmacological trials, and on the interaction of frailty on the efficacy of the treatments. We searched MEDLINE, EMBASE and Cochrane for clinical drug trials in older people. A total of 4031 abstracts were screened and 17 relevant studies were included in this review. We summarized the findings of these 17 trials into five main clinical areas: cardiovascular (eight studies), cognition (one study), vaccination (two studies), cancer (four studies) and other (two studies)...
March 21, 2024: British Journal of Clinical Pharmacology
#7
JOURNAL ARTICLE
A M García-Prieto, Ú Verdalles, A P de José, D Arroyo, I Aragoncillo, D Barbieri, R E Camacho, M Goicoechea
INTRODUCTION: Evidence about nefroprotective effect with RAAS blockers in elderly patients with chronic kidney disease (CKD) without proteinuria is lacking. The primary outcome of our study is to evaluate the impact of RAAS blockers in CKD progression in elderly patients without proteinuria. MATERIALS AND METHODS: Multicenter open-label, randomized controlled clinical trial including patients over 65 year-old with hypertension and CKD stages 3-4 without proteinuria...
March 19, 2024: Hipertensión y Riesgo Vascular
#8
REVIEW
Luis A Videla, Rodrigo Valenzuela, Jessica Zúñiga-Hernández, Andrea Del Campo
Obesity is a global health issue characterized by the excessive fat accumulation, leading to an increased risk of chronic noncommunicable diseases (NCDs), including metabolic dysfunction-associated fatty liver disease (MAFLD), which can progress from simple steatosis to steatohepatitis, fibrosis, cirrhosis, and hepatocellular carcinoma. Currently, there are no approved pharmacological protocols for prevention/treatment of MAFLD, and due the complexity lying beneath these mechanisms, monotherapies are unlikely to be efficacious...
March 20, 2024: Molecular Nutrition & Food Research
#9
JOURNAL ARTICLE
Jung-Yeon Choi, Hae-Young Lee, Ju-Hee Lee, Youjin Hong, Sue K Park, Dong Ryeol Ryu, Jang Hoon Lee, Seokjae Hwang, Kye Hun Kim, Sun Hwa Lee, Song-Yi Kim, Jae-Hyeong Park, Sang-Hyun Kim, Hack-Lyoung Kim, Jung Hyun Choi, Cheol-Ho Kim, Myeong-Chan Cho, Kwang-Il Kim
BACKGROUND: As the prevalence of hypertension increases with age and the proportion of the older population is also on the rise, research on the characteristics of older hypertensive patients and the importance of frailty is necessary. This study aimed to identify clinical characteristics of older hypertension in Korea and to investigate these characteristics based on frailty status. METHODS: The HOW to Optimize eLDerly systolic BP (HOWOLD-BP) is a prospective, multicenter, open-label, randomized clinical trial that aims to compare intensive (target systolic blood pressure [SBP] ≤ 130 mmHg) with standard (target SBP ≤ 140 mmHg) treatment to reduce cardiovascular events in older hypertensive Korean patients aged ≥ 65 years...
March 18, 2024: Journal of Korean Medical Science
#10
JOURNAL ARTICLE
Targeting Cell Senescence and Senolytics: Novel Interventions for Age-Related Endocrine Dysfunction.
Masayoshi Suda, Karl H Paul, Utkarsh Tripathi, Tohru Minamino, Tamara Tchkonia, James L Kirkland
Multiple changes occur in hormonal regulation with aging and across various endocrine organs. These changes are associated with multiple age-related disorders and diseases. A better understanding of responsible underling biological mechanisms could help in the management of multiple endocrine disorders over and above hormone replacement therapy (HRT). Cellular senescence is involved in multiple biological aging processes and pathologies common in elderly individuals. Cellular senescence, which occurs in many older individuals but also across the lifespan in association with tissue damage, acute and chronic diseases, certain drugs, and genetic syndromes, may contribute to such endocrine disorders as osteoporosis, metabolic syndrome, and type II diabetes mellitus (T2DM)...
March 19, 2024: Endocrine Reviews
#11
REVIEW
Upinder Kaur, Bhairav Kumar Pathak, Tharik Jalal Meerashahib, Dondapati Venkata Vamshi Krishna, Sankha Shubhra Chakrabarti
Despite advances in the management of type 2 diabetes mellitus (T2DM), one-third of patients with diabetes do not achieve the desired glycemic goal. Considering this inadequacy, many agents that activate glucokinase have been investigated over the last two decades but were withdrawn before submission for marketing permission. Dorzagliatin is the first glucokinase activator that has been granted approval for T2DM, only in China. As overstimulation of glucokinase is linked with pathophysiological disturbances such as fatty liver and cardiovascular issues and a loss of therapeutic efficacy with time...
March 9, 2024: Clinical Drug Investigation
#12
JOURNAL ARTICLE
Runguo Wu, Claire Williams, Junwen Zhou, Iryna Schlackow, Jonathan Emberson, Christina Reith, Anthony Keech, John Robson, Jane Armitage, Alastair Gray, John Simes, Colin Baigent, Borislava Mihaylova, Jane Armitage, Colin Baigent, Elizabeth Barnes, Lisa Blackwell, Rory Collins, Kelly Davies, Jonathan Emberson, Jordan Fulcher, Heather Halls, William G Herrington, Lisa Holland, Anthony Keech, Adrienne Kirby, Borislava Mihaylova, Rachel O'Connell, David Preiss, Christina Reith, John Simes, Kate Wilson, Michael Blazing, Eugene Braunwald, James de Lemos, Sabina Murphy, Terje R Pedersen, Marc Pfeffer, Harvey White, Stephen Wiviott, Michael Clearfield, John R Downs, Antonio Gotto, Stephen Weis, Bengt Fellström, Hallvard Holdaas, Alan Jardine, Terje R Pedersen, David Gordon, Barry Davis, Curt Furberg, Richard Grimm, Sara Pressel, Jeffrey L Probstfield, Mahboob Rahman, Lara Simpson, Michael Koren, Björn Dahlöf, Ajay Gupta, Neil Poulter, Peter Sever, Hans Wedel, Robert H Knopp, Stuart Cobbe, Bengt Fellström, Hallvard Holdaas, Alan Jardine, Roland Schmieder, Faiez Zannad, D John Betteridge, Helen M Colhoun, Paul N Durrington, John Fuller, Graham A Hitman, Andrew Neil, Eugene Braunwald, Barry Davis, C Morton Hawkins, Lemuel Moyé, Marc Pfeffer, Frank Sacks, John Kjekshus, Hans Wedel, John Wikstrand, Christoph Wanner, Vera Krane, Maria Grazia Franzosi, Roberto Latini, Donata Lucci, Aldo Maggioni, Roberto Marchioli, Enrico B Nicolis, Luigi Tavazzi, Gianni Tognoni, Jackie Bosch, Eva Lonn, Salim Yusuf, Jane Armitage, Louise Bowman, Rory Collins, Anthony Keech, Martin Landray, Sarah Parish, Richard Peto, Peter Sleight, John Jp Kastelein, Terje R Pedersen, Robert Glynn, Antonio Gotto, John Jp Kastelein, Wolfgang Koenig, Jean MacFadyen, Paul M Ridker, Anthony Keech, Stephen MacMahon, Ian Marschner, Andrew Tonkin, John Shaw, John Simes, Harvey White, Patrick W Serruys, Genell Knatterud, Gerard J Blauw, Stuart Cobbe, Ian Ford, Peter Macfarlane, Chris Packard, Naveed Sattar, James Shepherd, Stella Trompet, Eugene Braunwald, Christopher P Cannon, Sabina Murphy, Rory Collins, Jane Armitage, Louise Bowman, Richard Bulbulia, Richard Haynes, Sarah Parish, Richard Peto, Peter Sleight, Pierre Amarenco, K Michael Welch, John Kjekshus, Terje R Pedersen, Lars Wilhelmsen, Philip Barter, Antonio Gotto, John LaRosa, John Jp Kastelein, James Shepherd, Stuart Cobbe, Ian Ford, Sharon Kean, Peter Macfarlane, Chris Packard, Michele Roberston, Naveed Sattar, James Shepherd, Robin Young, Hiroyuki Arashi, Robert Clarke, Marcus Flather, Shinya Goto, Uri Goldbourt, Jemma Hopewell, G Kees Hovingh, George Kitas, Connie Newman, Marc S Sabatine, Gregory G Schwartz, Liam Smeeth, Jonathan Tobert, John Varigos, Junichi Yamamguchi
BACKGROUND: UK cardiovascular disease (CVD) incidence and mortality have declined in recent decades but socioeconomic inequalities persist. AIM: To present a new CVD model, and project health outcomes and the impact of guideline-recommended statin treatment across quintiles of socioeconomic deprivation in the UK. DESIGN AND SETTING: A lifetime microsimulation model was developed using 117 896 participants in 16 statin trials, 501 854 UK Biobank (UKB) participants, and quality-of-life data from national health surveys...
February 19, 2024: British Journal of General Practice
#13
JOURNAL ARTICLE
Camilla Fuchs Andersen, Julie Hempel Larsen, Jesper Jensen, Massar Omar, Nina Nouhravesh, Caroline Kistorp, Christian Tuxen, Finn Gustafsson, Filip K Knop, Julie Lyng Forman, Filip Soeskov Davidovski, Lars Thorbjørn Jensen, Kurt Højlund, Lars Køber, Lisbeth Antonsen, Mikael Kjær Poulsen, Morten Schou, Jacob Eifer Møller
INTRODUCTION: Sodium-glucose cotransporter 2 (SGLT2) inhibitors have previously demonstrated cardioprotective properties in patients with type 2 diabetes, suggesting a preventive effect on heart failure (HF). The Empire Prevent trial program investigates the therapeutic potential for HF prevention by evaluating the cardiac, metabolic, and renal effects of the SGLT2 inhibitor empagliflozin in patients with increased risk of developing HF, but without diabetes or established HF. METHODS: The Empire Prevent trial program is an investigator-initiated, double-blind, randomized clinical trial program including elderly and obese patients (60-84 years, body mass index >28 kg/m2 ) with at least one manifestation of hypertension, cardiovascular or chronic kidney disease, but no history of diabetes or HF...
February 14, 2024: American Heart Journal
#14
JOURNAL ARTICLE
Masato Nakamura, Hiroshi Inoue, Takeshi Yamashita, Masaharu Akao, Hirotsugu Atarashi, Takanori Ikeda, Yukihiro Koretsune, Ken Okumura, Wataru Shimizu, Shinya Suzuki, Hiroyuki Tsutsui, Kazunori Toyoda, Masahiro Yasaka, Takenori Yamaguchi, Satoshi Teramukai, Yoshiyuki Morishima, Masayuki Fukuzawa, Atsushi Takita, Atsushi Hirayama
Real-world data on coronary events (CE) in elderly patients with atrial fibrillation (AF) are lacking in the direct oral anticoagulant era. This prespecified sub-analysis of the ANAFIE Registry, a prospective observational study in > 30,000 Japanese patients aged ≥ 75 years with non-valvular AF (NVAF), investigated CE incidence and risk factors. The incidence and risk factors for new-onset CE (a composite of myocardial infarction [MI] and cardiac intervention for coronary heart diseases other than MI), MI, and cardiac intervention for coronary heart diseases other than MI during the 2-year follow-up were assessed...
February 13, 2024: Cardiovascular Intervention and Therapeutics
#15
JOURNAL ARTICLE
Chenglong Yu, Andrew Bakshi, Robin J Bell, Rakibul M Islam, David J Handelsman, John J McNeil, Paul Lacaze, Susan R Davis
BACKGROUND: Oestrone, predominantly made in fat, is the main circulating oestrogen and important for target tissue oestradiol production in women after menopause. The present study was undertaken to determine the genetic regulation of blood oestrone, measured with precision, in postmenopausal women and to explore associations between the identified genetic loci and endometrial cancer in a large, independent cohort. METHODS: A genome-wide association study (GWAS) was undertaken in women aged at least 70 years to identify genetic associations with blood oestrone concentrations measured by liquid chromatography and tandem mass spectrometry...
February 6, 2024: EBioMedicine
#16
JOURNAL ARTICLE
Matthew P Gilbert, Joan Skelly, Adrian F Hernandez, Jennifer B Green, Konstantin A Krychtiuk, Christopher B Granger, Lawrence A Leiter, John J V McMurray, Stefano Del Prato, Richard E Pratley
AIM: To analyse the effects of albiglutide, a glucagon-like peptide 1 receptor agonist, on cardiovascular outcomes in older adults aged ≥65 years with type 2 diabetes and cardiovascular disease who participated in the Harmony Outcomes trial (NCT02465515). MATERIALS AND METHODS: We conducted a post hoc analysis of the primary endpoint of the Harmony Outcomes trial-time to first occurrence of a major adverse cardiovascular event-in subgroups of participants aged <65 and ≥65 years and <75 and ≥75 years at baseline...
February 6, 2024: Diabetes, Obesity & Metabolism
#17
JOURNAL ARTICLE
James L Januzzi, Stefano Del Prato, Julio Rosenstock, Javed Butler, Justin Ezekowitz, Nasrien E Ibrahim, Carolyn S P Lam, Thomas Marwick, W H Wilson Tang, Yuxi Liu, Reza Mohebi, Alessia Urbinati, Faiez Zannad, Riccardo Perfetti
BACKGROUND: Diabetic cardiomyopathy (DbCM) is a form of Stage B heart failure (HF) at high risk for progression to overt disease. Using baseline characteristics of study participants from the Aldose Reductase Inhibition for Stabilization of Exercise Capacity in Heart Failure (ARISE-HF) Trial we sought to characterize clinical characteristics of individuals with findings consistent with DbCM. METHODS: Among study participants meeting inclusion criteria, clinical characteristics, laboratory testing, imaging, Kansas City Cardiomyopathy Questionnaire (KCCQ), Physical Activity Scale of the Elderly (PASE) and cardiopulmonary exercise testing (CPET) results were tabulated...
February 1, 2024: Cardiovascular Diabetology
#18
JOURNAL ARTICLE
Lujia Li, Xiaozheng Li, Yuerong Huang, Haojie Li, Cuihan Li, Yuxin Ma, Jianwei Zhang, Fang Peng, Shaojun Lyu
BACKGROUND: According to statistics, about one-fifth of the world's elderly people suffer from sleep disorders, and the problem of sleep disorders in the elderly is extremely serious, and this problem is one of the important causes of chronic diseases such as hypertension, hyperlipidemia, diabetes mellitus, and coronary heart disease in the elderly. The positive effect of Tai Chi exercise therapy on sleep problems has been confirmed, but at present, the effect of the specific duration of Tai Chi exercise on the improvement of elderly people with moderate to severe sleep disorders varies...
January 30, 2024: Heliyon
#19
REVIEW
Hesti Platini, Keyzha Amartya Adammayanti, Sidik Maulana, Putu Moradha Kharisma Putri, Welly Grivin Layuk, Juan Alessandro Jeremis Maruli Nura Lele, Hartiah Haroen, Sri Hartati Pratiwi, Faizal Musthofa, Arpit Mago
INTRODUCTION: Poorly controlled diabetes mellitus can lead to the development of diabetic foot ulcers (DFU), which is a frequent complication in patients. However, several diabetes management guidelines for older adults do not mention the occurrence of DFUs. Nowadays, Autologous Platelet-Rich Gel (APG) is being used for treating diabetic ulcers. APG is an innovative platelet-derived product with many advantages, such as being low-cost, easy to produce, and readily available materials...
2024: Therapeutics and Clinical Risk Management
#20
REVIEW
Muna A Adem, Boris Decourt, Marwan N Sabbagh
Type 2 diabetes mellitus (T2DM) and Alzheimer's disease (AD) are chronic, progressive disorders affecting the elderly, which fosters global healthcare concern with the growing aging population. Both T2DM and AD have been linked with increasing age, advanced glycosylation end products, obesity, and insulin resistance. Insulin resistance in the periphery is significant in the development of T2DM and it has been posited that insulin resistance in the brain plays a key role in AD pathogenesis, earning AD the name "type 3 diabetes"...
January 3, 2024: Biomedicines
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
